COST OF TREATMENT AND REDUCTION ACHIEVED BY CHRONIC ULCER IN DIABETIC PATIENTS - A COMPARISON BETWEEN HYDROGEL AND HUMAN RECOMBINANT EPIDERMAL GROWTH FACTOR